Guardant Health, Inc.

Guardant Health, Inc.

GHNYSE / NASDAQHealthcareSmall cap

$145.83+$0.24 (+0.2%)

Last close · Data as of Nov 20, 2026

Market cap
$17.6B
P/E
-42.4x
EV / EBITDA
-50.7x
Revenue
$982.0M
Net margin
-42.4%
ROCE
-25.6%

+45.4% over the last year

Guardant Health, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-10.3%
3M
-13.1%
6M
+26.8%
1Y
+45.4%
5Y
+49.4%

52-week range

Day change +$0.24 (+0.2%) from $146 to $146 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GH, bought on each weekday since 2021.

News & filings

What Guardant Health filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Current assets are 4.84 times current liabilities.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.

Read moreShow less

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.

Sector
Healthcare
Shares outstanding
130.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$17.6B
P/E
-42.4x
P/B
-177.7x
EV / EBITDA
-50.7x
EV / Sales
19.3x
P/S
18.0x
52-week high
$187.22
52-week low
$78.60

Profitability

Operating margin
-44.5%
Net margin
-42.4%
EBITDA margin
-38.1%
ROE
419.2%
ROCE
-25.6%
ROIC
-26.5%
ROA
-20.7%
Asset turnover
0.49

Growth

Revenue
$982.0M
Revenue growth, 1Y
32.9%
Revenue CAGR, 3Y
29.8%
Net profit growth, 1Y
-4.6%
Free cash flow
-$233.1M

Solvency

Current ratio
4.84
Debt / Equity
-17.22
Debt / Assets
0.85
CFO / Net profit
0.44
Cash / Market cap
2.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$982.0M
Cost of revenue$349.0M
Gross profit$633.0M
Operating expenses$1.1B
Research and development$364.2M
Selling, general and administrative$706.1M
Operating income-$437.3M
Interest and other$19.7M
Pretax income-$417.5M
Tax and other-$1.3M
Net income-$416.3M

Revenue and net profit

Revenue grew 32.9% in FY2025; net profit is the dashed line.

Guardant Health, Inc. revenue and net profit by fiscal year
Guardant Health, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$449.5M-$654.6M
FY2023$563.9M-$479.4M
FY2024$739.0M-$436.4M
FY2025$982.0M-$416.3M

Cash flows

FY2025: -$184.8M from operations, -$233.1M free after investment (dashed).

Guardant Health, Inc. operating and free cash flow by fiscal year
Guardant Health, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$309.5M-$386.9M
FY2023-$325.0M-$345.5M
FY2024-$239.9M-$274.9M
FY2025-$184.8M-$233.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$982.0M+32.9%1Y
EBITDA
-$373.9M
Net profit
-$416.3M
Cash from operations
-$184.8M
Free cash flow
-$233.1M
Revenue CAGR, 3Y
29.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$982.0M-$373.9M-$416.3M-$233.1M419.2%+32.9%-4.6%

Monthly returns

Month-by-month returns of GH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.0B
Liabilities$2.1B
Equity-$99.3M
Paid-in capital$2.9B
Retained earnings-$3.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GH highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Guardant Health, Inc. (this company)19.3x

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Guardant Health, Inc.GHthis company$17.6B-42.4x-177.7x419.2%-50.7x
BridgeBio Pharma, Inc.BBIO$13.2B-18.2x-6.3x34.7%-26.4x
Axsome Therapeutics, Inc.AXSM$11.9B-65.0x134.9x-207.5%-70.2x
Madrigal Pharmaceuticals, Inc.MDGL$11.4B-39.4x18.9x-47.8%-43.5x
Arrowhead Pharmaceuticals, Inc.ARWR$10.6B-6491.0x22.7x-0.3%65.9x
Cytokinetics, IncorporatedCYTK$9.8B——119.0%—
The Ensign Group, Inc.ENSG$9.6B27.9x4.3x15.4%19.9x
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Peer median—-21.7x5.9x7.5%-31.2x

Year-to-date ROI

GH since 1 January, against earlier years.

Historical volatility

GH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Guardant Health, Inc. operating margin by fiscal year
Guardant Health, Inc. operating margin by fiscal year
DateOperating margin
FY2022-121.1%
FY2023-100.1%
FY2024-60.0%
FY2025-44.5%
LineFY2025
Cost of revenueCost Of Revenue$349.0M
Gross profitGross Profit$633.0M
Operating expensesOperating Expense$1.1B
Research and developmentResearch And Development$364.2M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$1.4B
Pretax incomePretax Income-$417.5M

Learn while you research

Academy chapters picked for Guardant Health, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing33% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →